Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo E Mendes

Showing results (111-120 of 278) with videos related to

Pageof 28
Sort By:
The Journal of Antimicrobial Chemotherapy|October 30, 2008
Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance ProgramRodrigo E Mendes, Jan M Bell, John D Turnidge, et al.
Jac-Antimicrobial Resistance|October 5, 2022
Prevalence of carbapenemase genes among carbapenem-nonsusceptible <i>Enterobacterales</i> collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agentsMariana Castanheira, Lalitagauri M Deshpande, Rodrigo E Mendes, et al.
The Journal of Antimicrobial Chemotherapy|June 16, 2025
Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023)Helio S Sader, John H Kimbrough, Marisa L Winkler, et al.
Journal of Clinical Microbiology|February 24, 2026
Inference of ceftobiprole susceptibility through surrogate testing of ceftarolineHelio S Sader, Rodrigo E Mendes, David P Nicolau, et al.
International Journal of Antimicrobial Agents|December 27, 2017
Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016)Michael A Pfaller, Robert K Flamm, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2015
In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance ProgramSandra P McCurdy, Ronald N Jones, Rodrigo E Mendes, et al.
Diagnostic Microbiology and Infectious Disease|January 22, 2019
In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisionsMariana Castanheira, Andrew P Davis, Alisa W Serio, et al.
International Journal of Antimicrobial Agents|September 21, 2021
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitalsMariana Castanheira, Timothy B Doyle, Lalitagauri M Deshpande, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 21, 2012
In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010)David J Farrell, Mariana Castanheira, Rodrigo E Mendes, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|February 22, 2023
Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021)Helio S Sader, Cecilia G Carvalhaes, Michael D Huband, et al.
Pageof 28

Showing results (111-120 of 278) with videos related to

Sort By:
Pageof 28
The Journal of Antimicrobial Chemotherapy|October 30, 2008
Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance ProgramRodrigo E Mendes, Jan M Bell, John D Turnidge, et al.
Jac-Antimicrobial Resistance|October 5, 2022
Prevalence of carbapenemase genes among carbapenem-nonsusceptible <i>Enterobacterales</i> collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agentsMariana Castanheira, Lalitagauri M Deshpande, Rodrigo E Mendes, et al.
The Journal of Antimicrobial Chemotherapy|June 16, 2025
Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023)Helio S Sader, John H Kimbrough, Marisa L Winkler, et al.
Journal of Clinical Microbiology|February 24, 2026
Inference of ceftobiprole susceptibility through surrogate testing of ceftarolineHelio S Sader, Rodrigo E Mendes, David P Nicolau, et al.
International Journal of Antimicrobial Agents|December 27, 2017
Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016)Michael A Pfaller, Robert K Flamm, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2015
In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance ProgramSandra P McCurdy, Ronald N Jones, Rodrigo E Mendes, et al.
Diagnostic Microbiology and Infectious Disease|January 22, 2019
In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisionsMariana Castanheira, Andrew P Davis, Alisa W Serio, et al.
International Journal of Antimicrobial Agents|September 21, 2021
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitalsMariana Castanheira, Timothy B Doyle, Lalitagauri M Deshpande, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 21, 2012
In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010)David J Farrell, Mariana Castanheira, Rodrigo E Mendes, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|February 22, 2023
Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021)Helio S Sader, Cecilia G Carvalhaes, Michael D Huband, et al.
Pageof 28